SCHEMBL7129352

SCHEMBL7129352

CCOC(=O)c1ccc(C(=O)c2ccccc2N)cc1C(=O)O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 9/20 0.62
HSD17B10 Q99714 7/20 0.62
TSHR P16473 2/20 0.54
CDC25B P30305 4/20 0.54
CDC25A P30304 1/20 0.54
LMNA P02545 2/20 0.49
MAPT P10636 3/20 0.49
GAA P10253 2/20 0.49
ESRRA P11474 1/20 0.47
POLB P06746 2/20 0.46
RAB9A P51151 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
HPGD P15428 3/20 0.45
ALOX15 P16050 1/20 0.45
KDM4E B2RXH2 2/20 0.45
NPC1 O15118 3/20 0.44
TP53 P04637 2/20 0.44
CYP3A4 P08684 2/20 0.44
GLA P06280 1/20 0.44
MAPK1 P28482 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28542461 0.83 POLB (0.56) ALDH1A1HSD17B10TSHRCDC25BCDC25A
SCHEMBL7126704 0.83 LMNA (0.58) ALDH1A1HSD17B10TSHRCDC25BCDC25A
SCHEMBL1898128 0.82 POLB (0.54) ALDH1A1HSD17B10TSHRCDC25BCDC25A
Ethyl Anthranilate SCHEMBL27460908 0.82 ALDH1A1 (0.87) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL9695436 0.81 POLB (0.56) ALDH1A1HSD17B10TSHRCDC25BCDC25A
SCHEMBL8669772 0.80 CA12 (0.57) ALDH1A1TSHRLMNAMAPTRAB9A
SCHEMBL9008367 0.80 TSHR (0.56) ALDH1A1HSD17B10TSHRLMNAKDM4E
Ethyl Anthranilate SCHEMBL7560547 0.80 ALDH1A1 (0.96) ALDH1A1HSD17B10TSHRCDC25BMAPT
SCHEMBL12254208 0.80 TSHR (0.49) ALDH1A1HSD17B10TSHRCDC25BCDC25A
Water SCHEMBL27703024 0.79 TSHR (0.55) ALDH1A1HSD17B10TSHRLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics KRISTIANSEN MARIT (DK) 2003-10-02 US disclosed
US-6590118-B1 Used in treatment of and/or prevention of diabetes, especially non-insulin dependent diabetes (Type 2 diabetes) NOVO NORDISK A/S (DK) 2003-07-08 US disclosed
EP-1220832-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2002-07-10 EP disclosed
WO-2001023347-A1 NOVEL AROMATIC COMPOUNDS NOVO NORDISK A/S (DK) 2001-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030186944-A1 Such as 4-(2-(3-dimethylaminobenzoylamino)phenoxy)phthalic acid for treatment/prevention of diabetes; for inhibiting liver glycogen phosphorylase; dietetics PYGL, GYS2, PYGM ALDH1A1 901/4885HSD17B10 363/4885TSHR 3696/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.